Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Trial Examining Cellular Energetics Related to Various Wound Treatment Therapies

This study has been terminated.
(Study no longer met business objectives)
Information provided by (Responsible Party):
KCI USA, Inc. Identifier:
First received: December 20, 2007
Last updated: October 10, 2013
Last verified: October 2013
A randomized, controlled pilot study examining how cellular energetics related to various wound treatment therapies in patients with diabetic foot ulcers.

Condition Intervention
Diabetic Foot Ulcers
Device: Powered Suction Pump (VAC Freedom)
Device: Powered Suction Pump

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: A Randomized, Controlled Trial Examining Cellular Energetics Related To Various Wound Treatment Therapies

Resource links provided by NLM:

Further study details as provided by KCI USA, Inc.:

Primary Outcome Measures:
  • cellular energetics [ Time Frame: Day 0, Day 2, Day 7 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Normalized Lactate [ Time Frame: Day 0, Day 2, Day 7, Day 30 ] [ Designated as safety issue: No ]

Enrollment: 26
Study Start Date: July 2007
Study Completion Date: November 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: I Device: Powered Suction Pump (VAC Freedom)
continuous suction
Other Name: VAC Freedom
Active Comparator: II Device: Powered Suction Pump
continuous suction
Other Name: Gauze-Based Negative Pressure Wound Therapy Device


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type II diabetes
  • Subject has a diabetic foot ulcer 5cm squared or greater
  • Subject's diabetic foot ulcer is chronic

Exclusion Criteria:

  • HgbA1c of 12% or greater
  • Presence of cellulitis
  • Presence of osteomyelitis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00605189

United States, Ohio
The Ohio State University Medical Center
Columbus, Ohio, United States, 43210
United States, Texas
University of Texas Health Science Center San Antonio
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Study Director: Gayle M Gordillo, MD Ohio State University
  More Information

Responsible Party: KCI USA, Inc. Identifier: NCT00605189     History of Changes
Other Study ID Numbers: VACP2005-009 
Study First Received: December 20, 2007
Last Updated: October 10, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Diabetic Foot
Foot Ulcer
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases processed this record on October 21, 2016